Literature DB >> 2891703

Peptides derived from cleavage of prosomatostatin at carboxyl- and amino-terminal segments. Characterization of tissue and secreted forms in the rat.

Y C Patel1, W O'Neil.   

Abstract

Tissue and secreted forms of rat prosomatostatin and its cleavage products were characterized immunochemically using high performance liquid chromatography and sequence-specific radioimmunoassays directed against somatostatin-14 (S-14), S-28-(1-12), and S-28-(1-14). Acetic or hydrochloric acid extracts of hypothalamus, pancreas, stomach, and jejunum contained seven molecular forms of Mr = 10,400 (corresponding to prosomatostatin (pro-S], Mr = 6,800 (7-kDa peptide, consisting of an NH2-terminally truncated form of pro-S), Mr = 7,600 (8-kDa peptide, corresponding to pro-S-(1-76), i.e. pro-S minus the COOH-terminal -Arg-Lys-S-14), Mr = 5,600 (5-kDa peptide, corresponding to pro-S-(33-76)) and three peptides co-chromatographing with synthetic S-14, S-28, and S-28-(1-12). Acid/ethanol extracts of these tissues contained pro-S, 8-kDa peptide, S-28, S-14, and S-28-(1-12) forms, but not the 7- and 5-kDa species. Pepstatin inhibited 7- and 5-kDa peptide formation in acetic acid extracts of tissues. The secreted forms consisted of the same five forms present in acid/ethanol or acetic acid plus pepstatin tissue extracts. The 7- and 5-kDa peptides were not secreted and appeared to be derived artifactually, presumably through the action of renin- and cathepsin D-like acid proteases. Accurate quantitation of the 8-kDa peptide by acid/ethanol extraction revealed a variable tissue distribution. Since the presence of the 8-kDa form provides evidence for direct processing of pro-S----S-14 + 8-kDa peptide, the present data suggest that pro-S----S-14 conversion is important for S-14 synthesis in the hypothalamus and pancreas, tissues rich in the 8-kDa form, but not in the stomach and jejunal mucosa, which contain low concentrations of this peptide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2891703

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Tissue-specific distribution of cross-linked somatostatin receptor proteins in the rat.

Authors:  C B Srikant; K K Murthy; Y C Patel
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

Review 2.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 3.  Molecular biology of the regulation of hypothalamic hormones.

Authors:  J M Rondeel; I M Jackson
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

Review 4.  Drug design at peptide receptors: somatostatin receptor ligands.

Authors:  Jason P Hannon; Caroline Nunn; Barbara Stolz; Christians Bruns; Gisbert Weckbecker; Ian Lewis; Thomas Troxler; Konstanze Hurth; Daniel Hoyer
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

5.  Heterologous processing of rat prosomatostatin to somatostatin-14 by PC2: requirement for secretory cell but not the secretion granule.

Authors:  A S Galanopoulou; N G Seidah; Y C Patel
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

6.  Human seminal plasma contains somatostatin-64.

Authors:  L Odum; A H Johnsen
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

7.  Direct role of furin in mammalian prosomatostatin processing.

Authors:  A S Galanopoulou; N G Seidah; Y C Patel
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

Review 8.  Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms.

Authors:  Ryan W Mull; Anthony Harrington; Lucia A Sanchez; Yftah Tal-Gan
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

9.  N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population.

Authors:  Tore Hedbäck; Peter Almgren; Peter M Nilsson; Olle Melander
Journal:  J Clin Endocrinol Metab       Date:  2016-07-11       Impact factor: 5.958

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.